The initiative comes days after the launch of the Brazilian Association of the Indian Pharmaceutical Industry in Brasilia, intended to act as an institutional bridge between Indian drugmakers and the Brazilian market by facilitating partnerships, investments and regulatory compliance.
Trade and Investment Queensland (TIQ) brought an 18-member delegation representing 12 businesses, universities, and research institutions to BioAsia 2026 at the HITEX Exhibition Centre to forge partnerships with Indian companies. The delegation, marking one of the largest groups from Austral
Mumbai (Maharashtra) [India], February 9: Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordi
The conclusion of the India-European Union Free Trade Agreement (India-EU FTA) has opened major opportunities for the two regions to emerge as a global supplier of affordable and quality medicines, according to the Indian Pharmaceutical Alliance (IPA).
Indian Pharmaceutical Alliance on Tuesday welcomed the conclusion of the India-EU Free Trade Agreement, calling it an important milestone in strengthening bilateral trade. Secretary General, Indian Pharmaceutical Alliance, Sudarshan Jain said that the expected removal of EU tariffs of up
Hyderabad (Telangana) [India], January 23: Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharm
The Indian Pharmaceutical Market (IPM) concluded 2025 with a valuation of approximately Rs 2,40,672 crore, reflecting a value growth of 8.1 per cent. According to the Pharmarack Indian Pharma Industry Performance report, IPM is likely to maintain the same growth range of 7.8-8.1% in 2026 as
In India, the launch of generic semaglutide, expected in the first quarter of FY27, is projected to boost overall Indian Pharmaceutical Market (IPM) growth by 0.5-1%. Prices are anticipated to be 30-50% lower than current levels initially, with the potential for deeper cuts of up to 70-75% o
Union Minister for Health and Family Welfare and Chemicals and Fertilizers, J. P. Nadda, today released the Indian Pharmacopoeia 2026 (IP 2026) - the 10th edition of India's official book of drug standards at Dr. Ambedkar International Centre, New Delhi, marking a significant milestone in
Nadda highlighted that the Indian Pharmacopoeia serves as the official book of standards for drugs in the country and is a cornerstone of India's regulatory framework for pharmaceuticals. He stated that the 10th edition reflects scientific advancements, global best practices, and India's gro
Union Minister of Health and Family Welfare, Jagat Prakash Nadda, today reviewed the progress and initiatives of the Indian Pharmacopoeia Commission (IPC), in the presence of Nivedita Shukla Verma, Secretary, Department of Chemicals and Petro-Chemicals (DoCP) and holding additional charge
The growth of the Indian pharmaceuticals market (IPM) continues to remain muted in November, staying in single-digit territory for the past 32 months, Nomura said in its latest report.